Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.
Identifieur interne : 000057 ( Main/Exploration ); précédent : 000056; suivant : 000058Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.
Auteurs : Pengwei Luan [République populaire de Chine] ; Xinyue Ding [République populaire de Chine] ; Jiazhen Xu [République populaire de Chine] ; Lixian Jiang [République populaire de Chine] ; Yulan Xu [République populaire de Chine] ; Yuying Zhu [République populaire de Chine] ; Ruixiang Li [République populaire de Chine] ; Jiange Zhang [République populaire de Chine]Source :
- Life sciences [ 1879-0631 ] ; 2020.
Descripteurs français
- KwdFr :
- Animaux (MeSH), Apoptose (MeSH), Cellules cultivées (MeSH), Cytokines (métabolisme), Espèces réactives de l'oxygène (métabolisme), Extraits de plantes (pharmacologie), Glucose (déficit), Inflammation (anatomopathologie), Inflammation (métabolisme), Inflammation (traitement médicamenteux), Microglie (anatomopathologie), Microglie (effets des médicaments et des substances chimiques), Microglie (métabolisme), Neurones (anatomopathologie), Neurones (effets des médicaments et des substances chimiques), Neurones (métabolisme), Neuroprotecteurs (pharmacologie), Oxygène (métabolisme), Récepteur de type Toll-4 (métabolisme), Souris (MeSH), Transduction du signal (MeSH).
- MESH :
- anatomopathologie : Inflammation, Microglie, Neurones.
- déficit : Glucose.
- effets des médicaments et des substances chimiques : Microglie, Neurones.
- métabolisme : Cytokines, Espèces réactives de l'oxygène, Inflammation, Microglie, Neurones, Oxygène, Récepteur de type Toll-4.
- pharmacologie : Extraits de plantes, Neuroprotecteurs.
- traitement médicamenteux : Inflammation.
- Animaux, Apoptose, Cellules cultivées, Souris, Transduction du signal.
English descriptors
- KwdEn :
- Animals (MeSH), Apoptosis (MeSH), Cells, Cultured (MeSH), Cytokines (metabolism), Glucose (deficiency), Inflammation (drug therapy), Inflammation (metabolism), Inflammation (pathology), Mice (MeSH), Microglia (drug effects), Microglia (metabolism), Microglia (pathology), Neurons (drug effects), Neurons (metabolism), Neurons (pathology), Neuroprotective Agents (pharmacology), Oxygen (metabolism), Plant Extracts (pharmacology), Reactive Oxygen Species (metabolism), Signal Transduction (MeSH), Toll-Like Receptor 4 (metabolism).
- MESH :
- chemical , deficiency : Glucose.
- chemical , metabolism : Cytokines, Oxygen, Reactive Oxygen Species, Toll-Like Receptor 4.
- drug effects : Microglia, Neurons.
- drug therapy : Inflammation.
- metabolism : Inflammation, Microglia, Neurons.
- pathology : Inflammation, Microglia, Neurons.
- chemical , pharmacology : Neuroprotective Agents, Plant Extracts.
- Animals, Apoptosis, Cells, Cultured, Mice, Signal Transduction.
Abstract
AIMS
The aim of this study was to investigate the mechanism of pro-inflammatory phenotype transformation of microglia induced by oxygen-glucose deprivation (OGD), and how salvianolate regulates the polarization of microglia to exert neuroprotective effects.
MAIN METHODS
The immunofluorescence and western blot experiments were used to verify the injury effect on neuronal cells after inflammatory polarization of microglia. Secondly, immunofluorescence staining and western blot were analyzed inflammatory phenotype of microglia and TLR4 signaling pathway after salvianolate treatment. RT-qPCR and ELISA assays were showed the levels of RNA and proteins of inflammatory factors in microglia. Finally, flow cytometry and western blot assay proved that salvianolate had a certain protective effect on neuronal injury after inhibiting the phenotype of microglia.
KEY FINDINGS
The OGD condition could promote inflammation and activate of TLR4 signal pathway in microglia, and the polarization of microglia triggered caspase-3 signal pathway of neuronal cell. The optimal concentrations of salvianolate were incubated with microglia under OGD condition, which could reduce the reactive oxygen species (ROS) expression (P = 0.002) and also regulate the activity of SOD, CAT and GSH-px enzymes (P < 0.05). Moreover, salvianolate treatment could inhibit TLR4 signal pathway (P = 0.012), suppress the pro-inflammatory phenotype of microglia in OGD condition (P = 0.018), and reduce the expression of IL-6 and TNF-α (P < 0.05). Finally, neuronal damage induced by microglia under OGD condition was reversed after administration of the microglia supernatant after salvianolate treatment.
SIGNIFICANCE
Salvianolate, as an antioxidant, plays a neuroprotective role by inhibiting the pro-inflammatory phenotype and decreasing the expression of ROS in microglia.
DOI: 10.1016/j.lfs.2020.118393
PubMed: 32898527
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.</title><author><name sortKey="Luan, Pengwei" sort="Luan, Pengwei" uniqKey="Luan P" first="Pengwei" last="Luan">Pengwei Luan</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001</wicri:regionArea><wicri:noRegion>Zhengzhou 450001</wicri:noRegion></affiliation></author><author><name sortKey="Ding, Xinyue" sort="Ding, Xinyue" uniqKey="Ding X" first="Xinyue" last="Ding">Xinyue Ding</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Jiazhen" sort="Xu, Jiazhen" uniqKey="Xu J" first="Jiazhen" last="Xu">Jiazhen Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Lixian" sort="Jiang, Lixian" uniqKey="Jiang L" first="Lixian" last="Jiang">Lixian Jiang</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Yulan" sort="Xu, Yulan" uniqKey="Xu Y" first="Yulan" last="Xu">Yulan Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001</wicri:regionArea><wicri:noRegion>Zhengzhou 450001</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Yuying" sort="Zhu, Yuying" uniqKey="Zhu Y" first="Yuying" last="Zhu">Yuying Zhu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Li, Ruixiang" sort="Li, Ruixiang" uniqKey="Li R" first="Ruixiang" last="Li">Ruixiang Li</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Jiange" sort="Zhang, Jiange" uniqKey="Zhang J" first="Jiange" last="Zhang">Jiange Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: jgzhang@shutcm.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32898527</idno><idno type="pmid">32898527</idno><idno type="doi">10.1016/j.lfs.2020.118393</idno><idno type="wicri:Area/Main/Corpus">000056</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000056</idno><idno type="wicri:Area/Main/Curation">000056</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000056</idno><idno type="wicri:Area/Main/Exploration">000056</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.</title><author><name sortKey="Luan, Pengwei" sort="Luan, Pengwei" uniqKey="Luan P" first="Pengwei" last="Luan">Pengwei Luan</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001</wicri:regionArea><wicri:noRegion>Zhengzhou 450001</wicri:noRegion></affiliation></author><author><name sortKey="Ding, Xinyue" sort="Ding, Xinyue" uniqKey="Ding X" first="Xinyue" last="Ding">Xinyue Ding</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Jiazhen" sort="Xu, Jiazhen" uniqKey="Xu J" first="Jiazhen" last="Xu">Jiazhen Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Jiang, Lixian" sort="Jiang, Lixian" uniqKey="Jiang L" first="Lixian" last="Jiang">Lixian Jiang</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Xu, Yulan" sort="Xu, Yulan" uniqKey="Xu Y" first="Yulan" last="Xu">Yulan Xu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001</wicri:regionArea><wicri:noRegion>Zhengzhou 450001</wicri:noRegion></affiliation></author><author><name sortKey="Zhu, Yuying" sort="Zhu, Yuying" uniqKey="Zhu Y" first="Yuying" last="Zhu">Yuying Zhu</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Li, Ruixiang" sort="Li, Ruixiang" uniqKey="Li R" first="Ruixiang" last="Li">Ruixiang Li</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author><author><name sortKey="Zhang, Jiange" sort="Zhang, Jiange" uniqKey="Zhang J" first="Jiange" last="Zhang">Jiange Zhang</name><affiliation wicri:level="1"><nlm:affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: jgzhang@shutcm.edu.cn.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203</wicri:regionArea><wicri:noRegion>Shanghai 201203</wicri:noRegion></affiliation></author></analytic><series><title level="j">Life sciences</title><idno type="eISSN">1879-0631</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals (MeSH)</term><term>Apoptosis (MeSH)</term><term>Cells, Cultured (MeSH)</term><term>Cytokines (metabolism)</term><term>Glucose (deficiency)</term><term>Inflammation (drug therapy)</term><term>Inflammation (metabolism)</term><term>Inflammation (pathology)</term><term>Mice (MeSH)</term><term>Microglia (drug effects)</term><term>Microglia (metabolism)</term><term>Microglia (pathology)</term><term>Neurons (drug effects)</term><term>Neurons (metabolism)</term><term>Neurons (pathology)</term><term>Neuroprotective Agents (pharmacology)</term><term>Oxygen (metabolism)</term><term>Plant Extracts (pharmacology)</term><term>Reactive Oxygen Species (metabolism)</term><term>Signal Transduction (MeSH)</term><term>Toll-Like Receptor 4 (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux (MeSH)</term><term>Apoptose (MeSH)</term><term>Cellules cultivées (MeSH)</term><term>Cytokines (métabolisme)</term><term>Espèces réactives de l'oxygène (métabolisme)</term><term>Extraits de plantes (pharmacologie)</term><term>Glucose (déficit)</term><term>Inflammation (anatomopathologie)</term><term>Inflammation (métabolisme)</term><term>Inflammation (traitement médicamenteux)</term><term>Microglie (anatomopathologie)</term><term>Microglie (effets des médicaments et des substances chimiques)</term><term>Microglie (métabolisme)</term><term>Neurones (anatomopathologie)</term><term>Neurones (effets des médicaments et des substances chimiques)</term><term>Neurones (métabolisme)</term><term>Neuroprotecteurs (pharmacologie)</term><term>Oxygène (métabolisme)</term><term>Récepteur de type Toll-4 (métabolisme)</term><term>Souris (MeSH)</term><term>Transduction du signal (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Glucose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term><term>Oxygen</term><term>Reactive Oxygen Species</term><term>Toll-Like Receptor 4</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Inflammation</term><term>Microglie</term><term>Neurones</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Microglia</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term></keywords><keywords scheme="MESH" qualifier="déficit" xml:lang="fr"><term>Glucose</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Microglie</term><term>Neurones</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Inflammation</term><term>Microglia</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term><term>Espèces réactives de l'oxygène</term><term>Inflammation</term><term>Microglie</term><term>Neurones</term><term>Oxygène</term><term>Récepteur de type Toll-4</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Inflammation</term><term>Microglia</term><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Extraits de plantes</term><term>Neuroprotecteurs</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Neuroprotective Agents</term><term>Plant Extracts</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Inflammation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Apoptosis</term><term>Cells, Cultured</term><term>Mice</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Apoptose</term><term>Cellules cultivées</term><term>Souris</term><term>Transduction du signal</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>AIMS</b></p><p>The aim of this study was to investigate the mechanism of pro-inflammatory phenotype transformation of microglia induced by oxygen-glucose deprivation (OGD), and how salvianolate regulates the polarization of microglia to exert neuroprotective effects.</p></div><div type="abstract" xml:lang="en"><p><b>MAIN METHODS</b></p><p>The immunofluorescence and western blot experiments were used to verify the injury effect on neuronal cells after inflammatory polarization of microglia. Secondly, immunofluorescence staining and western blot were analyzed inflammatory phenotype of microglia and TLR4 signaling pathway after salvianolate treatment. RT-qPCR and ELISA assays were showed the levels of RNA and proteins of inflammatory factors in microglia. Finally, flow cytometry and western blot assay proved that salvianolate had a certain protective effect on neuronal injury after inhibiting the phenotype of microglia.</p></div><div type="abstract" xml:lang="en"><p><b>KEY FINDINGS</b></p><p>The OGD condition could promote inflammation and activate of TLR4 signal pathway in microglia, and the polarization of microglia triggered caspase-3 signal pathway of neuronal cell. The optimal concentrations of salvianolate were incubated with microglia under OGD condition, which could reduce the reactive oxygen species (ROS) expression (P = 0.002) and also regulate the activity of SOD, CAT and GSH-px enzymes (P < 0.05). Moreover, salvianolate treatment could inhibit TLR4 signal pathway (P = 0.012), suppress the pro-inflammatory phenotype of microglia in OGD condition (P = 0.018), and reduce the expression of IL-6 and TNF-α (P < 0.05). Finally, neuronal damage induced by microglia under OGD condition was reversed after administration of the microglia supernatant after salvianolate treatment.</p></div><div type="abstract" xml:lang="en"><p><b>SIGNIFICANCE</b></p><p>Salvianolate, as an antioxidant, plays a neuroprotective role by inhibiting the pro-inflammatory phenotype and decreasing the expression of ROS in microglia.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32898527</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>10</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0631</ISSN><JournalIssue CitedMedium="Internet"><Volume>260</Volume><PubDate><Year>2020</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Life sciences</Title><ISOAbbreviation>Life Sci</ISOAbbreviation></Journal><ArticleTitle>Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.</ArticleTitle><Pagination><MedlinePgn>118393</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0024-3205(20)31146-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lfs.2020.118393</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The aim of this study was to investigate the mechanism of pro-inflammatory phenotype transformation of microglia induced by oxygen-glucose deprivation (OGD), and how salvianolate regulates the polarization of microglia to exert neuroprotective effects.</AbstractText><AbstractText Label="MAIN METHODS" NlmCategory="METHODS">The immunofluorescence and western blot experiments were used to verify the injury effect on neuronal cells after inflammatory polarization of microglia. Secondly, immunofluorescence staining and western blot were analyzed inflammatory phenotype of microglia and TLR4 signaling pathway after salvianolate treatment. RT-qPCR and ELISA assays were showed the levels of RNA and proteins of inflammatory factors in microglia. Finally, flow cytometry and western blot assay proved that salvianolate had a certain protective effect on neuronal injury after inhibiting the phenotype of microglia.</AbstractText><AbstractText Label="KEY FINDINGS" NlmCategory="RESULTS">The OGD condition could promote inflammation and activate of TLR4 signal pathway in microglia, and the polarization of microglia triggered caspase-3 signal pathway of neuronal cell. The optimal concentrations of salvianolate were incubated with microglia under OGD condition, which could reduce the reactive oxygen species (ROS) expression (P = 0.002) and also regulate the activity of SOD, CAT and GSH-px enzymes (P < 0.05). Moreover, salvianolate treatment could inhibit TLR4 signal pathway (P = 0.012), suppress the pro-inflammatory phenotype of microglia in OGD condition (P = 0.018), and reduce the expression of IL-6 and TNF-α (P < 0.05). Finally, neuronal damage induced by microglia under OGD condition was reversed after administration of the microglia supernatant after salvianolate treatment.</AbstractText><AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">Salvianolate, as an antioxidant, plays a neuroprotective role by inhibiting the pro-inflammatory phenotype and decreasing the expression of ROS in microglia.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luan</LastName><ForeName>Pengwei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Xinyue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jiazhen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Lixian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yulan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Yuying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ruixiang</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiange</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Research Center of Chiral Drugs, Innovation Research Institute of Traditional, Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: jgzhang@shutcm.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Life Sci</MedlineTA><NlmUniqueID>0375521</NlmUniqueID><ISSNLinking>0024-3205</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C561960">salvianolate</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="Y">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017628" MajorTopicYN="N">Microglia</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Caspas-3 signal pathway</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Microglia</Keyword><Keyword MajorTopicYN="N">Neuronal apoptosis</Keyword><Keyword MajorTopicYN="N">ROS</Keyword><Keyword MajorTopicYN="N">TLR4 signal pathway</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>8</Day><Hour>20</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32898527</ArticleId><ArticleId IdType="pii">S0024-3205(20)31146-2</ArticleId><ArticleId IdType="doi">10.1016/j.lfs.2020.118393</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Luan, Pengwei" sort="Luan, Pengwei" uniqKey="Luan P" first="Pengwei" last="Luan">Pengwei Luan</name></noRegion><name sortKey="Ding, Xinyue" sort="Ding, Xinyue" uniqKey="Ding X" first="Xinyue" last="Ding">Xinyue Ding</name><name sortKey="Jiang, Lixian" sort="Jiang, Lixian" uniqKey="Jiang L" first="Lixian" last="Jiang">Lixian Jiang</name><name sortKey="Li, Ruixiang" sort="Li, Ruixiang" uniqKey="Li R" first="Ruixiang" last="Li">Ruixiang Li</name><name sortKey="Xu, Jiazhen" sort="Xu, Jiazhen" uniqKey="Xu J" first="Jiazhen" last="Xu">Jiazhen Xu</name><name sortKey="Xu, Yulan" sort="Xu, Yulan" uniqKey="Xu Y" first="Yulan" last="Xu">Yulan Xu</name><name sortKey="Zhang, Jiange" sort="Zhang, Jiange" uniqKey="Zhang J" first="Jiange" last="Zhang">Jiange Zhang</name><name sortKey="Zhu, Yuying" sort="Zhu, Yuying" uniqKey="Zhu Y" first="Yuying" last="Zhu">Yuying Zhu</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PlantImRecepV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PlantImRecepV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32898527
|texte= Salvianolate reduces neuronal apoptosis by suppressing OGD-induced microglial activation.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32898527" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PlantImRecepV1
| This area was generated with Dilib version V0.6.38. |  |